Last reviewed · How we verify
Pregabalin Dose Level 1
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury), Partial-onset seizures (adjunctive therapy), Generalized anxiety disorder.
At a glance
| Generic name | Pregabalin Dose Level 1 |
|---|---|
| Also known as | Lyrica Dose Level 1 |
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | Gabapentinoid; anticonvulsant; anxiolytic; analgesic |
| Target | Alpha-2-delta subunit of voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology; Pain Management; Psychiatry |
| Phase | Phase 3 |
Mechanism of action
By binding to presynaptic calcium channels, pregabalin decreases calcium influx and subsequently reduces the release of glutamate, norepinephrine, and substance P. This modulation of neurotransmitter release underlies its analgesic, anxiolytic, and anticonvulsant effects. The drug is thought to work through stabilization of hyperexcitable neural tissue rather than direct receptor antagonism.
Approved indications
- Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury)
- Partial-onset seizures (adjunctive therapy)
- Generalized anxiety disorder
- Fibromyalgia
Common side effects
- Dizziness
- Somnolence
- Dry mouth
- Edema (peripheral)
- Weight gain
- Blurred vision
- Ataxia
Key clinical trials
- Effect of Low-dose Pregabalin Retard (82.5 mg) Versus Standard-dose Pregabalin Retard (165 mg) on Postoperative Pain and Opioid Consumption After Elective Laparoscopic Abdominal Surgery: a Randomized, Double-blind, Controlled Trial (NA)
- Use of Driving Tests to Evaluate Patient Performance on Oral Opioids
- The Efficacy and Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibromyalgia (NA)
- Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy (NA)
- Electroacupuncture for PHN: Efficacy and Biomarker Evaluation in a Multicenter, Randomized, Sham-Controlled Trial Protocol (NA)
- Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting (PHASE4)
- To Evaluate the Effect of Food on the Pharmacokinetics of Y-4 Tablets in Healthy Subjects (PHASE1)
- Crisugabalin for Radiotherapy-Related Neuropathic Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: